We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+24.79%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$1.9B
AUM Growth
+$119M
Cap. Flow
+$19.1M
Cap. Flow %
1.01%
Top 10 Hldgs %
50.01%
Holding
78
New
5
Increased
8
Reduced
9
Closed
7

Top Buys

Rank Stock Value
1
AXSM icon
Axsome Therapeutics
AXSM
+$23.9M
2
GERN icon
Geron
GERN
+$18.1M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$17.6M
4
FATE icon
Fate Therapeutics
FATE
+$16.9M
5
APLS
Apellis Pharmaceuticals
APLS
+$14.4M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$22.1M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$20.7M
3
BPMC
Blueprint Medicines
BPMC
+$18.1M
4
VERU icon
Veru
VERU
+$17.7M
5
KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
+$8.25M

Sector Composition

Rank Sector Weight
1 Healthcare 99.67%
2 Financials 0.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CDAK
76
DELISTED
Codiak BioSciences, Inc. Common Stock
CDAK
– –
-488,157
Closed -$382K
OMEG
77
DELISTED
Omega Alpha SPAC Class A Ordinary Shares
OMEG
– –
-200,000
Closed -$1.99M
BLSA
78
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
– –
-500,000
Closed -$5.01M
1 2 3
4

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q4 2022 Portfolio in Review

As of Q4 2022, Boxer Capital held 78 positions worth $1.9B, up 6.7% from $1.78B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Boxer Capital's Q4 2022 filing shows 5 new, 8 increased, 9 reduced and 7 closed positions. Its largest new stake was Axsome Therapeutics: 400,000 shares worth $30.9M. The largest sale was Sarepta Therapeutics, an estimated $22.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Financials.

  • Boxer Capital's largest Q4 2022 buy was Axsome Therapeutics: 400,000 shares worth $30.9M.
  • Boxer Capital added most to Fate Therapeutics in Q4 2022, an estimated $16.9M increase.
  • Boxer Capital's biggest Q4 2022 reduction was Veru, cutting an estimated $17.7M.
  • Boxer Capital fully exited Sarepta Therapeutics in Q4 2022, selling an estimated $22.1M.
  • Boxer Capital's ten largest holdings make up 50% of its $1.9B portfolio in Q4 2022.
  • Boxer Capital opened 5 new positions and closed 7 in Q4 2022.
  • Boxer Capital's portfolio value rose 6.7% quarter-over-quarter to $1.9B.

Based on Boxer Capital's 13F filing for Q4 2022, filed 14 Feb 2023.